ASIT Biotech News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

05.12.19	ASIT biotech: Information on the Total Number of Voting Rights and Shares (Businesswire)
07.11.19	ASIT biotech: Information on the Total Number of Voting Rights and Shares (Businesswire)
22.07.19	ASIT biotech Raises EUR 9.225 Million in a Private Placement of Convertible Notes (Businesswire)
04.07.19	ASIT biotech: Information on the Total Number of Voting Rights and Shares (Businesswire)
06.06.19	ASIT biotech: Information on the Total Number of Voting Rights and Shares (Businesswire)
07.03.19	ASIT Biotech: Information on the Total Number of Voting Rights and Shares (Businesswire)
27.02.18	ASIT biotech: Information on the Total Number of Voting Rights and Shares (Businesswire)
12.02.18	ASIT biotech: Publication Related to a Transparency Notification (Businesswire)
12.02.18	ASIT biotech 2017 Annual Results: Ongoing ASIT+™ Products Development in Respiratory and Food Allergies (Businesswire)
30.01.18	ASIT biotech: Publication Related to a Transparency Notification (Businesswire)
29.01.18	ASIT biotech: Information on the Total Number of Voting Rights and Shares (Businesswire)
25.01.18	ASIT biotech Successfully Completes the First Tranche of Its Capital Increase and Raises €9.4 Million (Businesswire)
11.01.18	ASIT biotech is Publishing a New Article on the Clinical Result of gp-ASIT+TM In the Prestigious Science Journal ALLERGY (Businesswire)
14.12.17	ASIT biotech Reviews the Efficacy Results of gp-ASIT+™ Observed During the Phase III Trial Completed in 2016 (Businesswire)
08.12.17	ASIT biotech Shareholders Meeting Has Approved the Structure of the Next Financing Round (Businesswire)
06.12.17	ASIT biotech Significantly Moves Forward in the Preparation of the Clinical Development Plan of gp-ASIT+™ in the US (Businesswire)
01.12.17	ASIT biotech: 2018 Financial Calendar (Businesswire)
30.11.17	ASIT biotech: Newly Published Phase IIb Clinical Results with gp-ASIT+™ in the ALLERGY Journal Highlight Outstanding Clinical and Remarkable Immunological Effects (Businesswire)
23.11.17	European Patent Office Grants to ASIT biotech a Second Patent Related to the Active Ingredients Used in the ASIT+™ Allergy Immunotherapy Product Candidates (Businesswire)
07.11.17	ASIT biotech: Publishes the Documents Relating to the Extraordinary General Shareholders’ Meeting on 7 December 2017 (Businesswire)
07.11.17	In line with the business plan presented at the IPO, ASIT biotech prepares an additional fund raising to further develop its products (Businesswire)
24.10.17	ASIT biotech Publishes the Results of The hdm-ASIT+™ Phase I/II Follow-up Study in House Dust Mite Rhinitis (Businesswire)
17.10.17	ASIT biotech Announces the Grant of a European Patent on the Active Ingredients Used in the ASIT+™ Allergy Immunotherapy Product Candidates (Businesswire)
12.10.17	ASIT biotech Announces the Publication of Its First Clinical Data with gp-ASIT+™ in the Journal of Allergy and Clinical Immunology (JACI) (Businesswire)
14.09.17	ASIT biotech Announces the Publication of its 2017 Half-Year Financial Report (Businesswire)
14.09.17	ASIT biotech Presents Its 2017 Half-Year Results and Provides Update on Its Clinical Programs (Businesswire)
07.09.17	ASIT biotech to Publish Its Half-Year 2017 Results on Thursday 14 September 2017 (Businesswire)
30.11.16	ASIT Biotech has Completed the Recruitment of Its Phase IIa Clinical Study With hdm-ASIT+™ in House Dust Mite Rhinitis (Businesswire)
14.11.16	ASIT biotech takes important steps in US clinical development of gp-ASIT+™, its lead drug candidate for grass pollen rhinitis (Businesswire)
05.10.16	ASIT biotech announces the last patient last visit in the Phase III clinical study with its first product candidate gp-ASIT+™ for grass pollen rhinitis (Businesswire)
23.09.16	ASIT biotech Presents Its Results for the First Half of 2016 and Its Recent Clinical Breakthroughs (Businesswire)
21.06.16	ASIT Biotech Presents Its Recent Corporate Developments (Businesswire)
14.06.16	ASIT biotech: End of the Stabilization Period, Non-Exercise of the over-Allotment Option (Businesswire)
13.06.16	ASIT biotech: Setting up of a Liquidity Contract with Bank Degroof Petercam SA (Businesswire)
31.05.16	ASIT biotech: The Preliminary Documents for the Annual General Shareholder Meeting on 30 June 2016 Have Been Made Available (Businesswire)
26.05.16	ASIT biotech: Information on the Total Number of Voting Rights and Shares (Businesswire)
25.05.16	Transparency Notification Received from S.R.I.W. SA, EPIMEDE S.A., Mr R. De Spoelberch, SFPI Sa and SRIB SA & BRUSTART S.A. (Businesswire)
10.05.16	ASIT Biotech Raises Eur 23.5 Million in Successful Initial Public Offering (Businesswire)
10.05.16	ASIT Biotech Raises Eur 23.5 Million in Successful Initial Public Offering (Businesswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Holcim	91.22	1.56 %	K V
Sonova Hldg	319.70	1.56 %	K V
Lonza Grp	591.00	1.34 %	K V
Sika	231.50	1.27 %	K V
CieFinRichemont	171.70	0.94 %	K V
Swiss Re	138.05	-0.40 %	K V
Zurich Insur Gr	537.20	-0.52 %	K V
Kuehne+Nagel Int	204.60	-0.97 %	K V
Part Grp Hldg	1’389.50	-1.03 %	K V
Givaudan	3’818.00	-3.12 %	K V

Nachrichten zu ASIT Biotech S.A.

Aktien Top/Flop

Meistgelesene Nachrichten